retatrutide type 2 diabetes phase 2 results 2024 2025 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial New clinical trial results show

Psychiatry 52 , 924948 (2018)

RELATED: Retatrutide vs

Patients are expected to take the drug long term

Research presented at Heart Rhythm 2026 followed more than 13,000 patients and found GLP-1 medication use tied to a lower risk of atrial fibrillation, regardless of how much weight patients lost, including patients who gained weight

Long-Term Weight Loss and Metabolic Health Benefits Over multiple months of continuous dosing, participants in clinical trials exhibited improved insulin sensitivity, reduced blood sugar, lower blood pressure, and enhanced metabolic health markers

Eli Lillys diabetes drug Mounjaro has just been approved for obesity in the UK and it is developing another weight-loss drug, Retatrutide